Italia markets open in 6 hours 20 minutes

Perspective Therapeutics, Inc. (CATX)

NYSE American - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,7000+0,0200 (+1,19%)
Alla chiusura: 04:00PM EDT
1,7100 +0,01 (+0,59%)
Dopo ore: 07:50PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

    SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 (clinicaltrials.gov identifier NCT05655312), its targeted alpha-particle therapy, in development for the treatment of MC1R-positive metastatic melanoma. “We are encouraged by the pace of enrollment in the trial which we believe is indicativ

  • GlobeNewswire

    Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

    SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors Summary: This presentation

  • GlobeNewswire

    Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference

    SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long-term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer, as well as preliminary long-term data of Cesium-131 utilized in salvage tr